Pharmafile Logo
Pharmafocus logo
Advanced Search

Avycaz

Showing 5 posts of 5 posts found.

allergan

FDA approves first paediatric treatment for intra-abdominal and urinary tract infections in over 10 years

March 19, 2019
Manufacturing and Production, Sales and Marketing Allergan, Avycaz, FDA, pharma

Allergan has revealed that Avycaz (ceftazidime and avibactam) has been awarded an expansion of its label by the FDA to include …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

February 9, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Allergan, Antibiotics, Avycaz, Elastagen, FDA, GSK, India, J&J, JJ, Nektar Therapeutics, Novartis, Theravance, artificial intelligence, pharma

It’s top ten time again. This week, among our most popular stories was the worrying news that, accoridng to research …

News
allergan

Allergan’s Avycaz becomes first FDA-approved gram-negative antibiotic in over 15 years

February 2, 2018
Medical Communications, Sales and Marketing Allergan, Avycaz, FDA, pharma, pneumonia

Allergan has announced that the FDA has awarded approval to its fixed-dose combination antibacterial Avycaaz (ceftazidme and avibactam) for the …

News
allergan

FDA approves expanded label for Allergan’s Avycaz

June 24, 2016
Medical Communications, Research and Development, Sales and Marketing Allergan, Avycaz, FDA, expanded label

Allergan (NYSE: FDA) has announced that the US Food and Drug Administration (FDA) has approved its supplemental new drug application …

News
Actavis image

Actavis and AZ see FDA approval for ‘superbug’ drug

February 27, 2015
Research and Development, Sales and Marketing Actavis, AstraZeneca, Avycaz, FDA, US, ceftazidime/avibactam

Actavis and AstraZeneca’s combo ‘superbug’ drug Avycaz has been shown the green light to treat patients with complicated intra-abdominal infections …

News

Latest content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024